Ribo Submitted Phase 1 Trial Application for Obesity Drug
The company has filed a clinical trial application in the European Union to test the new siRNA candidate RBD3133.
Updated on Oct. 8, 2026 in Weight Loss
Live Poll
Do you believe the development of new obesity medications is moving in the right direction?
Suzhou Ribo Life Science has submitted a Phase 1 Clinical Trial Application for its new obesity therapeutic, RBD3133. The company aims to evaluate the safety and tolerability of the siRNA-based drug in participants with overweight or obesity.
Why it matters
The development of RBD3133 targets the INHBE gene, as human genetic research suggests that silencing this gene may improve metabolic function. This trial represents a critical first step in assessing a novel approach to addressing global obesity.
RBD3133 is an siRNA therapeutic designed to be administered subcutaneously to target the INHBE gene. The trial is a randomized, placebo-controlled study meant to assess pharmacokinetics and pharmacodynamics in humans.
The players
Suzhou Ribo Life Science
A biotechnology firm headquartered in Suzhou, China, that focuses on the development of innovative RNA-based therapeutics.
Ribocure Pharmaceuticals AB
A subsidiary company located in Mölndal, Sweden, that is involved in the international development of Ribo's drug pipeline.
The details
The drug candidate works by selectively silencing the INHBE gene, which encodes the protein activin E. By mimicking loss-of-function variants, researchers hope to achieve healthier fat distribution in patients with obesity or metabolic dysfunction.
Timeline
Ribo announced the successful submission of the clinical trial application on October 8, 2026.
Health Landscape
The push for RBD3133 follows an industry-wide shift toward RNA-based interventions for metabolic diseases. This submission marks a significant advancement in the development of siRNA therapeutics targeting complex health pathways.
For individuals managing obesity, this trial represents a potential expansion of future treatment options beyond existing therapies. However, the drug remains in early-stage development and is not yet available for patient use.
The takeaway
The pursuit of INHBE-targeted therapies highlights the potential for genetic science to revolutionize metabolic care. Readers should monitor future updates on the trial to understand how these findings might eventually impact clinical practice.
Further reading
Learn more about the latest innovations in Weight Loss research and development.
Live Poll
Do you believe the development of new obesity medications is moving in the right direction?
